Drug Trial Radar · NCT06826196
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
9
Actual
Start
Mar 24, 2025
Primary completion
Nov 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Aldena TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this first-in-human clinical trial is to learn if ALD-102 Solution is safe and well tolerated following injections in the scalp in subjects with alopecia areata. The study will also learn about the effect of ALD-102 on hair regrowth in treatment areas. The researchers will compare the effects of ALD-102 Solution (drug) to placebo (saline solution that contains no drug) or an untreated area. Study participants will have treatment areas selected on the scalp to receive ALD-102 Solution (drug), placebo (saline solution) or to remain untreated. Injections will occur once every 4 weeks for a treatment period of 8 weeks.
Conditions
- Alopecia Areata (AA)
Interventions
ALD-102 SolutionDrug
Treatment every 4 weeks for total of 8-week treatment period.
Placebo or ControlOther
Treatment every 4 weeks for 8-week treatment period
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse effects (AEs) and severe adverse effects (SAEs) as assessed by CTCAE, and injection site reactions (ISRs), evaluated by local tolerability assessments and numerical scales.Time frame: Clinical assessments during treatment and follow up period for a total of 24 weeks.
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
Clinical Trial Research Institute
Thousand Oaks, California
Options Research Group
West Lafayette, Indiana
The Brigham and Women's Hospital
Boston, Massachusetts
Lahey Clinic
Burlington, Massachusetts
Dermatology Specialists of Spokane
Spokane, Washington
The Centre for Clinical Trials
Oakville, Ontario, Canada
Innovaderm
Montreal, Quebec, Canada
Centre de Recherche Saint-Louis
Québec, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.